A5103246538- Innovations in Medical Education
- Lung Cancer Treatments and Mutations
- Advances in Oncology and Radiotherapy
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Radiopharmaceutical Chemistry and Applications
- Clinical Reasoning and Diagnostic Skills
- Brain Metastases and Treatment
- Health and Medical Research Impacts
- Gastric Cancer Management and Outcomes
- Bone and Dental Protein Studies
- Colorectal Cancer Surgical Treatments
- PI3K/AKT/mTOR signaling in cancer
- Digestive system and related health
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Esophageal Cancer Research and Treatment
- Global Cancer Incidence and Screening
- Oral and Maxillofacial Pathology
- Chronic Lymphocytic Leukemia Research
- Higher Education Learning Practices
- Cancer Research and Treatments
Queen's University
2006-2021
Cancer Care South East
2020
Kingston General Hospital
2019
Cancer Care Ontario
2008
Abstract Purpose: Osteopontin is a malignancy-associated protein measurable in blood and tumor tissue. To evaluate its prognostic value advanced disease, we conducted prospective clinical study measuring serial osteopontin plasma levels women with metastatic breast cancer throughout the course of their disease. Experimental Design: One hundred fifty-eight newly diagnosed were enrolled study. Plasma was measured using our validated ELISA, at baseline every 3 to 12 weeks during after therapy...
Timely lung cancer care has been associated with improved clinical outcomes and patient satisfaction. We identified improvement opportunities in management pathways at Kingston Health Sciences Centre. Quality strategies led to the implementation of a multidisciplinary clinic (MDC).We set an outcome measure decreasing time from diagnosis first treatment by 10 days within 6 months implementation. implemented weekly MDC that involved respirologists, medical oncologists, radiation oncologists...
After chemoradiation for localized non–small-cell lung cancer, surgery and prophylactic cranial irradiation (PCI) have been used as additional therapies. Less than a third of patients develop brain recurrences, or local recurrence their sole initial site recurrence; these are groups that would benefit from PCI surgery, respectively. Pretreatment identification more likely to be useful. A retrospective analysis 80 was performed determine prognostic factors such patterns failure. Twenty-nine...
Background: Globally there is a move to adopt competency-based medical education (CBME) at all levels of the training system. Implementation complex intervention such as CBME represents marked paradigm shift involving multiple stakeholders.
 Methods: This article aims share tips, based on review available literature and authors’ experiences, that may help educators implementing more easily navigate this major undertaking avoid “black ice” pitfalls encounter.
 Results: Careful...
3546 Background: Reo, a serotype 3 reovirus, may preferentially infect and destroy cells with RAS activation. This trial evaluated the progression-free survival (PFS) of untreated mCRC pts treated FOLFOX6/bevacizumab (q2 weekly) alone or Reo (3x1010TCID50 on day 1-5 [cycles 1, 2, 4, 6, 8 then alternate cycles]). Methods: The had 80% power to detect improvement in PFS from 8.5 15.5 mo [Hazard ratio (HR) 0.55, α = 0.1]. Primary analysis adjusted for stratification factors (prior adjuvant...
8046 Background: Selumetinib (AZD6244, ARRY-142886, S) is a potent inhibitor of MEK, with promising activity docetaxel in pts previously treated NSCLC. Non-clinical data suggest potential negative interaction platin. We conducted phase Ib study testing continuous or intermittent S either cisplatin/pemetrexed (CPe; non-squamous) carboplatin/paclitaxel (CPa) untreated Methods: Pts received CPa (C AUC 6; Pa 200mg/ m2) CPe 75mg/ m2 ; Pe 500mg/ for 4-6 21day cycles; single-agent continued. A 3+ 3...
10536 Background: This original research assesses Canadian Medical Oncology (MO) residents’ perceptions and satisfaction with their education preparedness for practice prior to initiation of Competency Based Education (CBME). Methods: Digital surveys were sent MO residents in training institutions yearly from 2014–2017. Because lower than expected response rates, invitations subsequently extended recent graduates completing between 2009–2014. Ethics funding granted by Queen’s University....
10514 Background: As part of a university wide initiative, CBME was implemented in our MO training program July 2017. Stages, Entrustable Professional Activity (EPA) assessments and Required Training Experiences established by the Royal College Physicians Surgeons Canada were adopted. MedTech Central, electronic portfolio developed at used for assessment collection. We share here observations experiences from first year implementation. Methods: Assessment metrics obtained through MEdTech....
25 Background: NCRT followed by surgery per the CROSS trial regimen is an accepted standard of care in treatment EC and GEJC. When treatments are used real-world setting, there often patient, potential outcome differences compared to original clinical trial. The study aim was assess application outcomes protocol. Methods: A retrospective chart review undertaken 83 patients (pts) with or GEJC who were treated from June 2012 2018 CRT. 65 pts intent proceed surgery. Pts’ demographics, clinical,...